121 related articles for article (PubMed ID: 19683004)
1. Structural basis of conserved cysteine in the fibroblast growth factor family: evidence for a vestigial half-cystine.
Lee J; Blaber M
J Mol Biol; 2009 Oct; 393(1):128-39. PubMed ID: 19683004
[TBL] [Abstract][Full Text] [Related]
2. Structure of a highly stable mutant of human fibroblast growth factor 1.
Szlachcic A; Zakrzewska M; Krowarsch D; Os V; Helland R; Smalås AO; Otlewski J
Acta Crystallogr D Biol Crystallogr; 2009 Jan; 65(Pt 1):67-73. PubMed ID: 19153468
[TBL] [Abstract][Full Text] [Related]
3. The interaction between thermodynamic stability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1.
Lee J; Blaber M
J Mol Biol; 2009 Oct; 393(1):113-27. PubMed ID: 19695265
[TBL] [Abstract][Full Text] [Related]
4. Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for "Second Generation" Therapeutic Application.
Xia X; Kumru OS; Blaber SI; Middaugh CR; Li L; Ornitz DM; Sutherland MA; Tenorio CA; Blaber M
J Pharm Sci; 2016 Apr; 105(4):1444-53. PubMed ID: 27019961
[TBL] [Abstract][Full Text] [Related]
5. Site-directed mutagenesis and molecular modeling identify a crucial amino acid in specifying the heparin affinity of FGF-1.
Patrie KM; Botelho MJ; Franklin K; Chiu IM
Biochemistry; 1999 Jul; 38(29):9264-72. PubMed ID: 10413500
[TBL] [Abstract][Full Text] [Related]
6. Effect of cysteine substitutions on the mitogenic activity and stability of recombinant human keratinocyte growth factor.
Bare LA; Brown M; Goyal S; Idler D; Mansson PE
Biochem Biophys Res Commun; 1994 Nov; 205(1):872-9. PubMed ID: 7999125
[TBL] [Abstract][Full Text] [Related]
7. Conversion of type I 4:6 to 3:5 beta-turn types in human acidic fibroblast growth factor: effects upon structure, stability, folding, and mitogenic function.
Lee J; Dubey VK; Somasundaram T; Blaber M
Proteins; 2006 Mar; 62(3):686-97. PubMed ID: 16355415
[TBL] [Abstract][Full Text] [Related]
8. Symmetric primary and tertiary structure mutations within a symmetric superfold: a solution, not a constraint, to achieve a foldable polypeptide.
Brych SR; Dubey VK; Bienkiewicz E; Lee J; Logan TM; Blaber M
J Mol Biol; 2004 Nov; 344(3):769-80. PubMed ID: 15533444
[TBL] [Abstract][Full Text] [Related]
9. Spackling the crack: stabilizing human fibroblast growth factor-1 by targeting the N and C terminus beta-strand interactions.
Dubey VK; Lee J; Somasundaram T; Blaber S; Blaber M
J Mol Biol; 2007 Aug; 371(1):256-68. PubMed ID: 17570396
[TBL] [Abstract][Full Text] [Related]
10. Redesigning symmetry-related "mini-core" regions of FGF-1 to increase primary structure symmetry: thermodynamic and functional consequences of structural symmetry.
Dubey VK; Lee J; Blaber M
Protein Sci; 2005 Sep; 14(9):2315-23. PubMed ID: 16081654
[TBL] [Abstract][Full Text] [Related]
11. Mutation choice to eliminate buried free cysteines in protein therapeutics.
Xia X; Longo LM; Blaber M
J Pharm Sci; 2015 Feb; 104(2):566-76. PubMed ID: 25312595
[TBL] [Abstract][Full Text] [Related]
12. Functional and structural bases of a cysteine-less mutant as a long-lasting substitute for galectin-1.
Nishi N; Abe A; Iwaki J; Yoshida H; Itoh A; Shoji H; Kamitori S; Hirabayashi J; Nakamura T
Glycobiology; 2008 Dec; 18(12):1065-73. PubMed ID: 18796645
[TBL] [Abstract][Full Text] [Related]
13. Design of fully active FGF-1 variants with increased stability.
Zakrzewska M; Krowarsch D; Wiedlocha A; Otlewski J
Protein Eng Des Sel; 2004 Aug; 17(8):603-11. PubMed ID: 15469994
[TBL] [Abstract][Full Text] [Related]
14. Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life.
Culajay JF; Blaber SI; Khurana A; Blaber M
Biochemistry; 2000 Jun; 39(24):7153-8. PubMed ID: 10852713
[TBL] [Abstract][Full Text] [Related]
15. Insights into the catalytic mechanism of the Bcp family: functional and structural analysis of Bcp1 from Sulfolobus solfataricus.
D'Ambrosio K; Limauro D; Pedone E; Galdi I; Pedone C; Bartolucci S; De Simone G
Proteins; 2009 Sep; 76(4):995-1006. PubMed ID: 19338062
[TBL] [Abstract][Full Text] [Related]
16. Participation of Cys123alpha of Escherichia coli succinyl-CoA synthetase in catalysis.
Hidber E; Brownie ER; Hayakawa K; Fraser ME
Acta Crystallogr D Biol Crystallogr; 2007 Aug; 63(Pt 8):876-84. PubMed ID: 17642514
[TBL] [Abstract][Full Text] [Related]
17. Structural and biochemical properties of fibroblast growth factor 23.
Yamashita T
Ther Apher Dial; 2005 Aug; 9(4):313-8. PubMed ID: 16076373
[TBL] [Abstract][Full Text] [Related]
18. Structure-function roles of four cysteine residues in the human arsenic (+3 oxidation state) methyltransferase (hAS3MT) by site-directed mutagenesis.
Song X; Geng Z; Zhu J; Li C; Hu X; Bian N; Zhang X; Wang Z
Chem Biol Interact; 2009 May; 179(2-3):321-8. PubMed ID: 19167370
[TBL] [Abstract][Full Text] [Related]
19. Functional importance of GGXG sequence motifs in putative reentrant loops of 2HCT and ESS transport proteins.
Dobrowolski A; Lolkema JS
Biochemistry; 2009 Aug; 48(31):7448-56. PubMed ID: 19594131
[TBL] [Abstract][Full Text] [Related]
20. Substitution of putative half-cystine residues in heparin-binding fibroblast growth factor receptors. Loss of binding activity in both two and three loop isoforms.
Hou J; Kan M; Wang F; Xu JM; Nakahara M; McBride G; McKeehan K; McKeehan WL
J Biol Chem; 1992 Sep; 267(25):17804-8. PubMed ID: 1325450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
